 |
| |
| Sep-20-17 | Downgrade |
Goldman |
Neutral → Sell |
$125 → $130 |
|
| Jul-21-17 | Downgrade |
BTIG Research |
Neutral → Sell |
$110 |
|
| Jul-21-17 | Downgrade |
Alembic Global Advisors |
Neutral → Underweight |
|
|
| Jul-20-17 | Resumed |
Credit Suisse |
Outperform |
$148 |
|
| Jul-05-17 | Reiterated |
Morgan Stanley |
Overweight |
$135 → $140 |
|
| May-18-17 | Reiterated |
Stifel |
Hold |
$124 → $128 |
|
| May-15-17 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| Jan-26-17 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Jan-25-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$133 → $128 |
|
| Oct-19-16 | Reiterated |
UBS |
Buy |
$137 → $144 |
|
| Jul-21-16 | Reiterated |
Deutsche Bank |
Hold |
$125 → $142 |
|
| Jul-20-16 | Reiterated |
UBS |
Buy |
$126 → $137 |
|
| Jul-20-16 | Reiterated |
RBC Capital Mkts |
Outperform |
$125 → $133 |
|
| May-20-16 | Initiated |
Standpoint Research |
Sell |
$94 |
|
| Apr-20-16 | Reiterated |
RBC Capital Mkts |
Outperform |
$122 → $125 |
|
| Apr-20-16 | Reiterated |
Piper Jaffray |
Neutral |
$105 → $106 |
|
| Apr-15-16 | Reiterated |
RBC Capital Mkts |
Outperform |
$114 → $122 |
|
| Mar-14-16 | Upgrade |
Goldman |
Sell → Neutral |
|
|
| Dec-01-15 | Upgrade |
Barclays |
Equal Weight → Overweight |
$101 → $115 |
|
| Oct-05-15 | Resumed |
Piper Jaffray |
Neutral |
$105 |
|
|
|
| Sep-24-17 09:18AM | Could This Be Warren Buffett's Greatest Weakness? Motley Fool |
| Sep-22-17 05:19PM | FDA declines to approve J&J arthritis drug sirukumab Reuters |
| 04:33PM | U.S. FDA rejects J&J's arthritis drug Reuters |
| 04:18PM | Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson Motley Fool |
| 12:19PM | Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : September 22, 2017 Capital Cube |
| 09:07AM | What Pfizers Valuation Changes after 2Q17 Tell Us Market Realist |
| 08:59AM | Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com Zacks |
| 08:42AM | Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update Zacks |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| Sep-21-17 10:49PM | J&J Was Alerted to Risk of Asbestos in Talc in 70s, Files Show Bloomberg |
| 04:00PM | Johnson & Johnson : JNJ-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers : September 21, 2017 Capital Cube |
| 02:49PM | J&J? Its Time to Sell on Valuation: Goldman Sachs Investopedia |
| 01:00PM | Research Shows That Canadian Military Servicemembers and First Responders Struggle to Get Support for Their Own Health Needs CNW Group |
| 10:55AM | Karyopharm's Liposarcoma Candidate Superior in Phase II Study Zacks |
| 10:25AM | Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake Zacks |
| 09:35AM | Pharma giants' to clash in court over biosimilar product dispute American City Business Journals |
| 09:15AM | 3 Stocks to Help You Make Money in Retirement Motley Fool |
| 09:08AM | A Venerable Vanguard Dividend ETF Benzinga |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| 06:48AM | This squabble between two big drugmakers could have major implications for the U.S. health care system MarketWatch |
| 12:44AM | [$$] The Murky World of Drug Rebates Gets Airing in Lawsuit The Wall Street Journal |
| 12:43AM | [$$] Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies The Wall Street Journal |
| 12:41AM | PRESS DIGEST - Wall Street Journal - Sept 21 Reuters |
| Sep-20-17 08:46PM | Pfizer and Johnson & Johnson's Brewing Brawl Gets Real Motley Fool |
| 07:09PM | Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners TheStreet.com |
| 06:46PM | [$$] Pfizer Alleges J&J Thwarted Competition to Remicade, in Legal Test of Biotech-Drug Copies The Wall Street Journal |
| 04:47PM | Top Research Reports for Northrop Grumman, BNY Mellon & Celgene Zacks |
| 03:46PM | Pfizer is taking its fight with J&J over a blockbuster drug to court Business Insider |
| 03:42PM | [$$] Pfizer takes on J&J with antitrust lawsuit Financial Times |
| 03:23PM | Pfizer files suit against J&J over Remicade contracts Reuters |
| 02:18PM | J&J: You Can Only Stretch That Valuation So Far Barrons.com |
| 02:17PM | [$$] Murky World of Drug Rebates Gets Airing in Lawsuit The Wall Street Journal |
| 01:46PM | Goldman cuts one key Dow component to a "sell" CNBC Videos |
| 01:45PM | Cramer: Goldman's Downgrade Of J&J Is 'Questionable' TheStreet.com |
| 01:25PM | Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell' TheStreet.com |
| 11:49AM | Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers Benzinga |
| 10:18AM | Pfizer files suit against J&J over Remicade contracts Reuters |
| 09:11AM | Sell Johnson & Johnson because of its 'stretched' valuation: Goldman CNBC |
| 08:46AM | Morning Movers: General Mills Slumps, Johnson & Johnson Slips, American Airlines Gains Barrons.com |
| 08:01AM | 3 Dividend Stocks That Should Pay You the Rest of Your Life Motley Fool |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| 06:32AM | Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool |
| Sep-19-17 06:14PM | [$$] Johnson & Johnson Acquires Contact Lens Service Sightbox The Wall Street Journal |
| 11:58AM | The only thing Trump is doing to end the opioid crisis rewards the companies that started it Business Insider |
| 10:37AM | Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia Zacks |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| Sep-18-17 04:32PM | Portland's Sightbox sold to health care behemoth American City Business Journals |
| 02:21PM | 3 Dividend Stocks Ideal for Your Golden Years Motley Fool |
| 12:09PM | My Buy and Sell Ratings on the 20 Largest Stocks GuruFocus.com |
| 10:23AM | Catalyst (CPRX) Focused on Two Lead Pipeline Candidates Zacks |
| 10:15AM | J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU Zacks |
| 10:00AM | Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks |
| 10:00AM | Q2 2017 S&P 500 Buybacks Fall 9.8% from Q1, to $120.1 Billion PR Newswire |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| 07:39AM | Abbott Laboratories 375th Consecutive Quarterly Dividend Market Realist |
| Sep-17-17 12:59PM | 3 Stocks to Hold for the Next Century Motley Fool |
| 09:18AM | Don't Make This Huge Mistake With Celgene Motley Fool |
| 08:34AM | 10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright Motley Fool |
| Sep-15-17 05:16PM | The Smartest Move Johnson & Johnson Has Made All Year Motley Fool |
| 04:32PM | [$$] JNJ May Benefit From Celltrion Issues Barrons.com |
| 01:30PM | Ridiculously Weak U.S. Dollar Will Make These 10 Companies Huge Winners TheStreet.com |
| 01:18PM | Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily |
| 10:36AM | Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study Zacks |
| 09:57AM | Johnson & Johnson Is Getting Ready for Another Upside Breakout TheStreet.com |
| 08:46AM | Abbotts Amplatzer Device Affirms Reduced Recurrent Stroke Rates Market Realist |
| 08:40AM | European panel backs Janssen's psoriasis drug Reuters |
| 08:15AM | Pfizer Punches Back at Johnson & Johnson in Prostate Cancer Motley Fool |
| 08:04AM | European panel recommends approval of J&J's psoriasis drug Reuters |
| Sep-14-17 07:50PM | How to spot market rotations CNBC Videos |
| 06:45PM | Cramer's No. 1 rule for spotting market rotations CNBC Videos |
| 06:31PM | ETFs with exposure to Johnson & Johnson : September 14, 2017 Capital Cube |
| 05:15PM | Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results PR Newswire |
| 11:22AM | These party drugs could become the answer for clinically ... CNBC Videos |
| 11:00AM | Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx Zacks |
| 10:01AM | Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod Zacks |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| 03:30AM | Astra's Farxiga results may open up type 1 diabetes opportunity Reuters |
| Sep-13-17 11:29AM | Johnson & Johnson :JNJ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube |
| 09:29AM | Integra Divests Assets to Natus, Paves Way for Codman Buyout Zacks |
| 09:00AM | Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies PR Newswire |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| Sep-12-17 11:39AM | Achillion's HCV Partnership with J&J Terminated, Stock Falls Zacks |
| 10:09AM | Johnson & Johnson breached its 50 day moving average in a Bullish Manner : JNJ-US : September 12, 2017 Capital Cube |
| 09:14AM | Valeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy InvestorPlace |
| 09:06AM | Assessing Mercks Immunology and Cardiovascular Franchise in 2Q17 Market Realist |
| 08:00AM | See what the IHS Markit Score report has to say about Johnson & Johnson. Markit |
| Sep-11-17 04:30PM | Federated, Carnival, Alphabet climb; Regeneron skids Associated Press |
| 04:30PM | Why Achillion Pharmaceuticals Crashed 22.2% Today Motley Fool |
| 04:12PM | S&P 500 Reaches New Record as Stocks Rally Amid Subsiding Irma, North Korea Fears TheStreet.com |
| 01:48PM | Dow, S&P 500 on Track for Best Day in 6 Months as Irma Worries Ease TheStreet.com |
| 01:34PM | Low-Volatility ETFs Can Help Investors Ride Out A Market Pullback Barrons.com |
| 09:46AM | Achillion Shares Are Plunging on Termination of Hepatitis C Pact TheStreet.com |
| 08:50AM | Achillion Pharma Slides After Hep C Deal Is Terminated 24/7 Wall St. |
| 08:34AM | Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends CNBC |
| 07:51AM | Early movers: HCI, UVE, HRTG, XL, RE, JNJ, PPC, TEVA, AAPL & more CNBC |
| Sep-10-17 03:14PM | Johnson & Johnson, 3M and 8 Other Winners From the Ridiculously Weaker Dollar TheStreet.com |
| 07:10AM | 2 Dividend Stocks You Can Buy and Hold Forever Motley Fool |
| Sep-09-17 10:06AM | US Market Indexes Mostly Lower Friday With Losses for the Week GuruFocus.com |
| Sep-08-17 08:06PM | 3 Top Index Funds to Keep You in the Investing Game Motley Fool |
| 03:00PM | Johnson & Johnson, 3M and 8 Other Winners From the Ridiculously Weaker Dollar TheStreet.com |
|
|
|
|
| Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising brand adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Option Exercise | 72.54 | 102,692 | 7,449,278 | 230,342 | Jul 26 11:49 AM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Jul 24 | Sale | 133.14 | 102,692 | 13,672,629 | 127,650 | Jul 26 11:49 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Option Exercise | 61.75 | 82,591 | 5,099,994 | 226,693 | Jul 24 11:06 AM | | Caruso Dominic J | Exec VP, Finance; CFO | Jul 20 | Sale | 136.72 | 82,591 | 11,291,478 | 144,102 | Jul 24 11:06 AM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Mar 03 | Option Exercise | 59.76 | 50,000 | 2,987,780 | 118,536 | Mar 07 04:21 PM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Mar 03 | Sale | 123.62 | 50,000 | 6,181,140 | 68,536 | Mar 07 04:21 PM | | Kapusta Ronald A | Controller, CAO | Feb 28 | Option Exercise | 72.54 | 14,543 | 1,054,949 | 44,507 | Mar 02 05:50 PM | | Kapusta Ronald A | Controller, CAO | Feb 28 | Sale | 122.26 | 14,543 | 1,777,954 | 29,964 | Mar 02 05:50 PM | | Pruden Gary J | Exec VP, WW Chair, Med Devices | Feb 28 | Sale | 122.21 | 16,299 | 1,991,943 | 43,630 | Mar 02 05:16 PM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 15 | Sale | 117.29 | 22,000 | 2,580,274 | 127,650 | Feb 16 06:53 PM | | Caruso Dominic J | Exec VP, Finance; CFO | Feb 13 | Option Exercise | 0.00 | 26,947 | 0 | 150,700 | Feb 15 10:00 PM | | Kapusta Ronald A | Controller, CAO | Feb 13 | Option Exercise | 0.00 | 2,148 | 0 | 30,052 | Feb 16 06:01 AM | | Pruden Gary J | Exec VP, WW Chair, Med Devices | Feb 13 | Option Exercise | 0.00 | 15,532 | 0 | 63,405 | Feb 16 06:01 AM | | Duato Joaquin | Exec VP, WW Chair, Pharma | Feb 13 | Option Exercise | 0.00 | 22,298 | 0 | 75,814 | Feb 16 06:01 AM | | Fasolo Peter | Exec VP, Chief HR Officer | Feb 13 | Option Exercise | 0.00 | 15,598 | 0 | 68,899 | Feb 16 06:01 AM | | Gorsky Alex | Chairman, CEO | Feb 13 | Option Exercise | 0.00 | 84,299 | 0 | 280,617 | Feb 16 06:01 AM | | PETERSON SANDRA E | Exec VP, Group WW Chairman | Feb 13 | Option Exercise | 0.00 | 27,667 | 0 | 69,436 | Feb 16 06:01 AM | | Stoffels Paulus | Exec VP, Chief Scientific Off | Feb 13 | Option Exercise | 0.00 | 26,447 | 0 | 156,125 | Feb 16 06:01 AM | | Ullmann Michael H | Exec VP, General Counsel | Feb 13 | Option Exercise | 0.00 | 14,600 | 0 | 114,866 | Feb 16 06:01 AM | | Ullmann Michael H | Exec VP, General Counsel | Feb 01 | Option Exercise | 65.62 | 27,735 | 1,819,971 | 119,190 | Feb 03 12:05 PM | | Ullmann Michael H | Exec VP, General Counsel | Feb 01 | Sale | 112.88 | 21,735 | 2,453,442 | 97,455 | Feb 03 12:05 PM | | PRINCE CHARLES | Director | Oct 21 | Buy | 114.11 | 875 | 99,846 | 26,520 | Oct 25 01:52 PM |
|
|
|
|
|
|
